EUROFINS NV20 Share Price Euronext Paris
Equities
ERFNV
FR0013462876
Healthcare Facilities & Services
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
560 EUR | +1.82% | -.--% | -.--% |
05-31 | EUROFINS SCIENTIFIC : EPS cut (2023: -28.6%, 2024: -18.4%) | |
05-13 | Eurofins Scientific to Expand US Battery Materials Testing Capabilities | MT |
Sales 2024 * | 7.05B 7.65B 601B | Sales 2025 * | 7.6B 8.24B 647B | Capitalization | 10.68B 11.58B 909B |
---|---|---|---|---|---|
Net income 2024 * | 397M 431M 33.81B | Net income 2025 * | 530M 575M 45.14B | EV / Sales 2024 * | 1.96 x |
Net Debt 2024 * | 3.15B 3.41B 268B | Net Debt 2025 * | 3.12B 3.38B 265B | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
27
x | P/E ratio 2025 * |
21.1
x | Employees | - |
Yield 2024 * |
1.04% | Yield 2025 * |
1.41% | Free-Float | 66.78% |
Latest transcript on EUROFINS NV20
1 day | +1.82% |
Managers | Title | Age | Since |
---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 61 | 31/12/86 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 31/12/14 |
Christian Wurst
COO | Chief Operating Officer | - | 30/09/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 61 | 31/12/86 |
Yves-Loïc Martin
BRD | Director/Board Member | 58 | 31/12/91 |
Valérie Hanote
BRD | Director/Board Member | 58 | 31/12/90 |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.52% | 88.99B | |
-24.52% | 74.82B | |
-5.56% | 25.03B | |
+4.31% | 17.88B | |
-14.25% | 16.43B | |
+2.97% | 15.77B | |
+79.20% | 13.21B | |
+70.11% | 13.08B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- ERF Stock
- ERFNV Stock